Effect of rosiglitazone on glucose tolerance in newly-diagnosed type 2 diabetes patients
10.3760/cma.j.issn.1000-6699.2010.12.006
- VernacularTitle:罗格列酮对初发2型糖尿病患者糖耐量的影响及相关因素
- Author:
Baocheng CHANG
;
Tong WANG
;
Chunyan SHAN
;
Miaoyan ZHENG
;
Yun XIE
;
Lirong SUN
;
Lihua ZHANG
;
Liming CHEN
;
Ping FENG
- Publication Type:Journal Article
- Keywords:
Rosiglitazone;
Diabetes;
Glucose tolerance;
Restoration
- From:
Chinese Journal of Endocrinology and Metabolism
2010;26(12):1035-1037
- CountryChina
- Language:Chinese
-
Abstract:
One hundred and thirteen newly-diagnosed type 2 diabetic patients were treated with rosiglitazone for 16 weeks. Glucose tolerance was restored in 46 cases ( group A), but not restored in 67 cases (group B). Compared with group B,the patients of group A were younger and had shorter course of diabetes and lower body mass index (BMI,P<0.05); Homeostasis model assessment for β-cell function (HOMA-β) and earlyphase insulin secretion in group A were better than those of group B before and after treatment respectively (P<0. 05 ) ,while homeostasis model assessment for insulin resistance ( HOMA-IR )in group A was lower than that of group B before treatment (P<0. 05 ). In conclusions, rosiglitazone improved insulin resistance of type 2 diabetes patients, thus facilitated restoration of β-cells function and glucose tolerance. The related factors of glucose tolerance restoration included age ,diabetes duration, BMI, HbA1 c, β-cells function, and insulin resistance.